Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis

Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis

Abstract Background Combining Trastuzumab with chemotherapy for HER2-positive gastric cancer shows treatment promise but may raise costs. We aimed to evaluate the cost-effectiveness of combining Trastuzumab with chemotherapy for HER2-positive gastric cancer treatment in Iran. Methods We employed a p...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Kaveh, Nashmil Ghadimi, Amirhossein Zarei Alvar, Kamran Roudini, Rajabali Daroudi
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Health Economics Review
Subjects:
Trastuzumab
Gastric neoplasms
Economic evaluation
Cost-effectiveness
Iran
Online Access:https://doi.org/10.1186/s13561-024-00571-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items